Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Clinical pharmacokinetics - 1 Apr 2018

Geenen Jill J J, Linn Sabine C, Beijnen Jos H, Schellens Jan H M

Abstract excerpt

Breast cancer is a heterogeneous disease, manifesting in a broad differentiation in phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 and 20% of all breast cancers are triple negative. Triple-negative breast cancer (TNBC) lacks the expression of human epidermal growth factor receptor 2 (HER2) and hormone receptors; therefore, to date, chemotherapy remains the backbone of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Homologous Recombination

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Treatment Outcome

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 29063517
DOI: 10.1007/s40262-017-0587-4

Genes

ATM
BRCA1
PALB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.PMID 29063517Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

PARP inhibitors in the management of breast cancer: current data and future prospects.Semantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future PerspectivesSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read ↗

Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.Semantic proximity Read ↗

An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity Read ↗

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.